NRG1 and myeloid sarcoma: These findings, along with our current study on the inflammatory axis of LncRNA Ftx/miR-382-5p/NRG1, emphasize the growing potential of biomarkers in improving diagnostic precision and differentiating MS from other conditions, such as NMO.